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Abstract

In response to the many neurological disorders that plague humanity, no treatment shows more
promise than stem cell therapy. By using these special cells to regrow damaged neurons and
combat sources of disease in affected patients, researchers hope to treat neurological disorders of
all kinds. While great strides have been made in laboratory settings, the widespread use of stem
cells to treat neurological disorders in humans is still a distant goal. Recent advancements have
been made in the area of neural stem cell therapy, but complications arise when using this
method to treat neurological disorders.

NEURAL STEM CELL THERAPY

4

Applications and Challenges of Neural Stem Cell Therapy
Stem cells possess the remarkable ability to develop into many different types of cells
and are the foundation of every tissue and organ system of the human body. While all stem cells
can self-renew and differentiate, different types of stem cells have a range of abilities. For
example, embryonic stem cells are those that have been extracted from the blastocyst, a mass of
cells that forms days after a human egg cell has been fertilized by a sperm. These cells are
valuable for their pluripotent ability, or the ability to transform into every cell in the body, except
for placental or umbilical cord cells. Tissue-specific stem cells, on the other hand, are adult stem
cells that are housed in a specific organ and can transform into any cell of the same organ. While
using these cells to combat disease shows enormous potential, the many setbacks that have
occurred when transplanting stem cells show that advancements need to be made for widespread
use of this method to be possible (Alison et al., 2002).
One of the most promising applications of stem cell therapy lies in the prospect of using
these specialized cells to treat neurological disorders. Neurological disorders such as
Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cerebrovascular diseases, and many
others arise when some factor induces the destruction of nervous tissue. When a neurological
disorder causes damage to the neurons of these individuals, long-term and potentially permanent
effects can arise due to the inability of most neurons to regenerate. This is due to the amitotic
nature of neurons, meaning that the DNA copying of these cells is impeded by a lack of
centrioles, making them unable to enter mitosis. While this might seem like a flaw, the
specialized functions that neurons perform to transfer signals throughout the body require
neurons to establish widespread interneuron connections (Frotscher, 1992). The addition of new
neurons by the replication process would harm these functions by taking energy away from
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signal transduction and interfering with established neural connections. The goal of neural stem
cell therapy is to combat damage caused to these neurons by inducing the differentiation of new
neurons.
While the inability of neurons to reproduce is constant throughout much of the body,
there is evidence that neural reproduction (neurogenesis) occurs in two main regions of the body:
the subventricular zone (SVZ) and the subgranular zone of the dentate gyrus (Haas et al., 2005).
In addition to this finding, it has also been found that neural stem cells (NSCs) exist in the
striatum, spinal cord, and neocortex of the central nervous system. The NSCs in these areas
persist throughout the lifetime of humans and are exogenously modulated by external signals.
When signaled by factors such as an enriched environment, physical activity, or stress,
neurogenesis begins.
Therapeutic Process
Neural stem cell therapy begins with the culturing and replication of NSCs in laboratory
conditions. While there are multiple ways to obtain NSCs, researchers need to be aware of the
limitations of each method. The first way that these cells can be obtained is by extracting them
directly from neural tissues such as the subgerminal zone in adults or the neuroectoderm in
fetuses (Boese et al., 2018). Once obtained, the stem cells are grown on media, and growth
factors are added to increase expansion. Another method used to obtain neural stem cells is to
derive them from embryonic stem cells in vivo. This technique, however, is limited by the vast
amount of manipulation that is required to cause the embryonic stem cells to differentiate into
NSCs instead of other cell types. To maximize neural stem cell yield, certain compounds need to
be introduced into the embryonic stem cell culture to inhibit differentiation into other cell types.
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In addition to the previous two techniques, there also exists a method for obtaining NSCs
by reprogramming somatic cells to reproduce stem cells. iPSCs, which are human-induced
pluripotent stem cells, have been created by using vectors to introduce new genes into somatic
cells, causing them to reproduce stem cells instead of somatic cells. One benefit of using iPSCs
to generate neural stem cells is there are fewer ethical concerns than traditional methods of
deriving stem cells from human embryos. This is especially important due to the knowledge that
such types of embryos are increasingly often showing developmental autonomy and even
viability (Denker, 2021). However, when working with iPSCs, a limitation exists in having to
navigate the lengthy procedure of taking already differentiated somatic cells and reprogramming
them back into their normal state. Another method similar to this involves using defined growth
factors to directly cause the differentiation of somatic cells into neural stem cells (Boese et al.,
2018). This method shows much promise because, in addition to limiting ethical concerns
regarding extracting fetal tissue and reducing the risk of immune system complications, the
lengthy process of turning somatic cells into iPSCs is avoided.
Once NSCs have been obtained, they must be grafted into the target issue and
successfully migrate to the site of neural damage for therapeutic effects to be performed. In many
cases, it has been found that cells transplanted into the brain to treat injury form clusters near the
site of injection and demonstrate a low migratory capacity (Ladewig et al., 2014). One
hypothesis for this occurrence is that the level of maturity of the transplanted cells is important
when hoping to achieve proper cellular migration. In a preclinical study, cortical neuroepithelial
stem cells (cNESC) were derived from iPSCs and transplanted into a rat stroke model 7 days
post-injury (Payne et al., 2018). Before transplantation, the cNESC cells were arrested in three
different stages of differentiation: early-, mid-, and late-stages. At the end of the study, it was
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found that a higher number of graft cells were observed to survive in rats receiving the early- and
mid-stage differentiated stem cells. This shows that the level of stem cell maturity should be
considered when seeking to establish cell lines for transplantation.
Chemoattraction is another factor to consider when investigating NSC migration. Many
studies have demonstrated the remarkable chemoreceptive abilities of NSCs. When grafted into a
tissue of interest, these cells will naturally migrate towards areas of injury. This is due to
chemokine receptors that allow NSCs to recognize areas of increased pro-inflammatory
chemokine expression (Boese et al., 2018). While this can be a helpful property of NSCs, it can
also work to counter migration. It has been found that factors such as fibroblast growth factor 2
(FGF2) and vascular endothelial growth factor (VEGF), which are naturally expressed by neural
progenitor cells, can act as chemoattractants for NSCs, pulling them away from injury sites
(Ladewig et al., 2014). To counter this, researchers have used FGF2 and VEGF inhibitors to pretreat soon-to-be grafted cells. It was found that by using this method, more transplanted cells
underwent proper migration and less densely packed engraftment was observed one-week posttransplantation. Once neural stem cells arrive at an injury site, they can begin to reproduce
neurons to make up for those that have been damaged or destroyed.
Neural stem cell therapy, being a relatively new therapeutic technique, has shown both
extreme promise and various complications. Some of the successes of neural stem cell therapy
have come from preclinical studies on animal models, where results suggest that behavioral
recovery after neurological damage is the result of new neural connections being established
between the brain and grafted NSCs (Cardoso et al., 2018). These new neural connections
support the conclusion that the implanted neural stem cells were able to overcome compatibility
obstacles with the animal host and effectively treat disease. Additionally, clinical trials on
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patients with Parkinson’s disease have been conducted where grafted fetal dopaminergic neurons
were able to improve motor function (Lindvall et al., 1992). While these results are encouraging,
complications also exist in using neural stem cell therapy to treat neurological disorders. For
example, in clinical trials involving the implantation of NSCs, adverse post-surgery effects such
as immune reactions and tumor growth have arisen, and the survivability of grafted neural stem
cells has been shown to vary widely between trials (Li et al., 2007). For neural stem cell therapy
to be ready for wide employment as the premier method for neurological disease treatment,
researchers need to uncover solutions to these complex obstacles.
Immune Response to Transplantation
Much of the difficulties in transplanting NSCs come from the body’s natural reaction to
foreign material, which is to generate an immune response. This response, although quantifiable,
can vary based on the type of transplant being conducted. An autograph transplant, for example,
involves grafting self-tissue into another area of the same individual (Punt et al., 2019).
Autograft transplants have a high likelihood of avoiding the generation of a severe immune
response because the transplanted tissue is derived from the same individual it will be
transplanted into and hence will not contain “anti-self” markers in the graft tissue. Another type
of transplant, an isograft transplant, also avoids generating a harmful immune response by
grafting tissue that comes from genetically identical individuals such as identical twins. Since
these individuals contain the same genetic code, they also contain most of the same cell markers.
Unfortunately, most organ transplants today require xenograft or allograft transplants, which are
when an organ or tissue is transplanted between different species or separate individuals of the
same species, respectively. In both of these types of transplants, tissue rejection is common and
follows a predictable clinical course
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In the first stage of graft rejection, called hyperacute rejection by preexisting antibody,
rejection occurs before graft tissue can revascularize, due to complement pathways being
activated by antibodies (Salado-Manzano et al., 2020). These pathways target graft tissue shortly
after it is transplanted into a host. Following this stage, acute rejection occurs via mediation by
T-cell responses. In this stage, alloantigens expressed on cells of the foreign graft are recognized
by CD4+ and CD8+ T cells and proliferate in response (Punt et al., 2019). Usually, acute rejection
occurs a week or two after transplantation has occurred. Chronic phase rejection, the last stage of
transplant rejection, occurs due to both cell-mediated and humoral responses to graft tissue.
Unfortunately, this phase of rejection is very dangerous because it can occur months or even
years after acute rejection reactions to transplanted tissue have subsided. Currently, the survival
rates of individuals receiving grafted tissues and organ transplants are the highest in history, but,
even so, clinical research is currently being conducted to attempt to discover allograft
transplantation techniques that would avoid generating harmful immune responses and risking
tissue rejection altogether.
Avoiding Harmful Inflammation
After neurological disorders such as stroke take place, it is common for harmful
inflammation to be generated, causing secondary damage to both the central and peripheral
nervous systems. This inflammation is caused by the actions of the body’s innate and adaptive
inflammatory mechanisms (Lee et al., 2008). This process begins when neutrophils and
macrophages initiate the infiltration of microglia into the brain. Following this cell migration, the
site of neurological damage experiences widespread activation of inflammatory cytokines and
chemokines. Next, the major cytokines, nuclear factor-kappa B (NF-kB) and tumor necrosis
factor-alpha (TNF-α) are activated by the spleen, generating a systemic inflammatory response.
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Due to the unique ability of neural stem cells to facilitate the regeneration of damaged
neurological tissue, its promise for treating common disorders such as stroke is unmatched.
Recently, it has been found that NSCs are even more valuable in medicine due to their
remarkable abilities to attenuate the production of a harmful inflammatory response. The method
by which grafted neural stem cells accomplish inflammatory attenuation is known as the
“bystander effect” (Lee et al., 2008). During this action, NSCs show chaperone-like roles to
modulate their surrounding environment and use immune-like functions to induce the regulated
cell death, or apoptosis, of encephalitogenic T-cells. Additionally, NSCs have also been shown
to suppress the adaptive immune system, which leads to decreased peripheral inflammation
generation.
Because one of the chief causes of transplant rejection is widespread inflammation, it is
clear to see why it is so important that NSCs alleviate this concern. While most transplantation
surgeries require dangerous immunosuppressive treatments before a procedure is viable, NSCs
can create an environment safe enough for graft tissue to survive in a new host without the
involvement of outside pharmaceuticals. In this way, continued research into advancing the
natural anti-inflammatory and immunosuppressive abilities of NSCs may allow future patients
with neurological disorders such as stroke, Parkinson’s disease, or dementia to heal in a way that
does not risk developing a serious or even life-threatening infection.
Genetic Modification
An additional strategy to improve the viability of neural stem cell transplantation is
employing genetic modification to improve both the survival rate and therapeutic function of
transplanted cells. Through gene editing, researchers have been able to insert exogenous genes
into the NSC’s genome, allowing much larger numbers of grafted cells to survive implantation.
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While one of the most promising functions of NSCs is their natural immunosuppressant and antiinflammatory abilities, which help to avoid the risk of generating rejection, there have been
concerns in the medical community about whether genetic modification of NSCs will lead to the
generation of an increased immune response. These concerns have mostly arisen from data on
other genetically modified stem cells, such as mesenchymal stem cells (MSCs), which show
harsh immunological reactions following genetic modification (Wei et al., 2021). However, if
researchers can genetically modify NSCs while retaining their ability to thwart tissue rejection, a
new avenue for treating neurological disorders could be opened.
In a recent study, NSCs were genetically modified with the magnetosome membranespecific gene before transplantation into host tissue (Wei et al., 2021). As major
histocompatibility complex (MHC) classes I and II play important roles in the regulation of
immunological responses, the research focused on analyzing these complexes as well as
modified NSCs, astrocytes, and microglia. While the concentrations of astrocytes, microglia, and
MHC molecules were found to have increased immediately following transplantation, it was
discovered that the concentrations of these cells and molecules were decreased overall after three
weeks. Also, when these results were compared to studies with non-transgenetic NSCs, it was
found that genetically modified NSCs were not responsible for the aggravation of immunological
responses.
Immunosuppressive Therapy
Because the innate immunosuppressive abilities of NSCs, while remarkable, may not be
fully able to limit harmful responses enough to avoid rejection, therapeutics may still need to be
employed to mitigate risks. In a recent study on human embryonic stem cells (hESCs), tissue
regeneration and recovery have been observed in animal models of Parkinson’s disease (Snow et
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al., 2019). Since hESCs can differentiate into virtually any cell type in the body, it can be
reasonably assumed that the neurological recovery observed in the previous study stemmed from
the cells’ differentiation into neural tissue. When evaluating the viability of using hESCs to treat
immunocompetent versus immunosuppressant animal models (mice), it was discovered that the
survival rate of the immunocompetent mice with grafted hESCs was far below that of the
immunosuppressed mice containing grafted hESCs (Swijnenburg et al., 2008). This is due to
cellular and humoral immune responses characterized by inflammatory cell infiltration and
subsequent immune-mediated rejection of hESCs in immunocompetent animals. Drawn from the
above study, it can be concluded that immunosuppressive techniques can lead to a decreased
chance of transplant rejection, even in stem cells that are being used to treat neurological
diseases.
Development of Lineage Control
One of the leading complications of neural stem cell therapy is the complexity of
controlling NSC differentiation. If a solution is not found for this problem, NSC transplants may
become widely unavailable for fear of creating large populations of unwanted cell types. One
possible solution to this problem comes from the immobilization of growth factors and
cytokines, molecules that can modify stem cell function (Li et al., 2014). For these growth
factors to be successfully delivered to the area of interest, researchers have engineered scaffolds
that provide a matrix for cell attachment, migration, and differentiation. In a recent study,
researchers successfully used a modified chitosan hydrogel system to encourage neural stem cell
differentiation with adsorbed and immobilized growth factors.
The chitosan scaffold that was employed in this experiment was found to successfully
deliver growth factors to NSCs, and, as a result, allowed researchers to control the specific
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lineages being created. For example, researchers delivered the growth factor interferon-γ (IFNγ) to direct the NSC production of neuronal cell types, platelet-derived growth factor-AA
(PDGF-AA) to direct the production of oligodendrocytes, and bone morphogenic protein-2
(BMP-2) to direct the production of astrocytes (Li et al., 2014). While these results were
obtained from research involving cell cultures, they show much promise for application to
human disease. If researchers can use a similar scaffold to the one used in this experiment to
apply growth factors to the human spinal cord, for example, expectations could be made for
guiding structures that would replicate the developmental formation of the CNS and replace
damaged tissue. In this way, the applications for partnering this biotechnology with NSCs to treat
sites of neurological damage are enormous.
Alzheimer’s Disease
Of the many neurodegenerative disorders that plague humanity, Alzheimer’s disease
(AD) has recently become among the most prevalent. AD is characterized by progressive
impairment of memory and other cognitive functions, and it is currently estimated that one in
every ten people over the age of 65 in the United States is afflicted by this disease (Hebert et al.,
2013). With the prevalence of this disease and the resulting toll it has on society increasing as the
population of the United States ages, a considerable amount of research is currently being
conducted to find new treatment methods for this currently incurable disease.
While the many factors that lead to the development of AD are complex, much evidence
supports a few specific hypotheses relating to the onset of this disease. To start, the amyloidcascade hypothesis has shown that the accumulation of amyloid-β in the parenchyma and
cerebral blood vessels triggers many of the events leading to neurodegeneration (Hardy &
Selkoe, 2002). When amyloid-β accumulates in these areas of the brain, it has been found that
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the structural integrity of the blood-brain barrier, a brain structure that serves a critical function
in brain homeostasis as well as the clearance of amyloid-β from the central nervous system,
degrades significantly. Interestingly, it has also been found that in rare cases, individuals
exhibiting homozygosity for genes controlling amyloid-β production have exhibited partial
protection from neurodegeneration (Hampel et al., 2021). In these instances, the rare mutation
being exhibited allows the individual to continue normal cognitive functioning, even in the
presence of a severe number of amyloid-β plaques. However, the patients exhibiting these genes
eventually developed dementia-like symptoms as a result of amyloid-β and neurofibrillary tangle
accumulation. As a result of these discoveries, it has become essential for AD researchers to
focus their efforts on finding new ways to prevent both the accumulation of amyloid-β and the
degradation of the blood-brain barrier.
As NSC therapy shows great promise for treating neurological disorders, it is thought that
the facilitation of neural recovery by this method offers the greatest chance of defeating AD. In
addition to replacing dead or injured brain cells, NSCs’ previously discussed use of the bystander
effect in addition to microenvironment modulation showcase this method’s ability to combat
many of the precipitating factors of AD (Lee et al., 2007). More specifically, treatments for AD
are focusing on two different avenues: delivering therapeutics during the chronic stage of AD to
alleviate already developed symptoms and delivering NSCs during the early stages of
neurodegeneration with the goal of NSC migration to injury sites to combat early AD pathology
(Boese et al., 2020). The avenue that aims to treat the chronic symptoms of AD would be critical
for those currently suffering from AD-induced neurodegeneration. To repair neurodegeneration
that has already occurred, NSCs' ability to rapidly proliferate and replace damaged cells would
be critical. Additionally, NSCs’ secretion of therapeutic products could potentially lead to
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increased functioning of the blood-brain barrier, which would contribute to limiting the damage
caused by amyloid-β buildup. The second avenue, treating the early onset of AD, requires
researchers to be able to identify the signs of developing neurodegenerative disease. A few of
these critical biomarkers, which have been linked to AD development, are the concentration of
amyloid-β in cerebrospinal fluid (CSF) and blood and the imaging of tau deposits by positron
emission tomography (PET; Brier et al., 2016). With these methods, clinicians of the future may
be able to screen those with genetic dispositions for AD and schedule at-risk individuals for NSC
therapy.
As with most novel scientific developments, there are currently limitations to using NSCs
to treat AD. One of the most cumbersome of these limitations is the previously mentioned
inability to fully control the cell types of NSC differentiation. While it has been found that NSC
therapy leads to the generation of neurological tissue, in many cases, animal trials have seen
NSC implantation stimulate unwanted differentiation into non-neural cell types and uncontrolled
generation of glial cells (Xuan et al., 2009). It is essential that these complications are resolved
before humans can hope to be treated by NCS therapy, as the overproduction of glial cells could
lead to severe complications, such as inflammation. Another complication that has been
discovered during NSC research is the decline of NSC content in the brain with age (Manganas
et al., 2007). If not resolved, this could cause a person undergoing NSC treatment to need many
grafts of stem cells before seeing results and could even limit the efficacy of using NSCs to treat
some individuals.
Parkinson’s Disease
Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by
bradykinesia, rigidity, and tremor. Generally, these symptoms are caused by the gradual loss of
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nigrostriatal dopamine (DA) neurons and the subsequent neuronal degeneration. While the
current treatments that exist for PD have been successful at relieving a range of symptoms, no
widespread treatment exists to counteract the progression of this disease. With the everincreasing popularity of research focusing on using stem cells and tissue transplants to counter
disease, current studies are working to explore these avenues for PD treatment.
One strategy that has yielded results has been to provide patients with intrastriatal grafts
of human fetal ventral mesencephalic (hfVM) tissue. This has shown that grafted tissue of DAproducing neurons can replace dead DA neurons by transplantation (Politis & Lindvall, 2012).
With this method, grafts can provide a population of DA-producing neuronal cells that lasts up to
16 years and have been known to provide some symptomatic relief. While this sounds promising,
the results from studies involving hfVM grafts have been inconsistent and hindered by the
creation of adverse effects such as graft-induced dyskinesias (GIDs). Additionally, there are
considerable ethical dilemmas amongst researchers on the use of human fetal stem cells for
disease treatment. Because of these drawbacks, different methods of treating PD are still needed
to gain widespread support. Stem cells could potentially solve this problem by providing an
ethical and endless supply of DA neurons for transplantation.
To develop methods of treating PA with stem cells, researchers have used gene
modification technology to reprogram adult fibroblasts into induced pluripotent stem cells. Once
these iPSCs are formed, they can differentiate into DA-ergic neurons, raising the possibility of
generating an unlimited supply of replacement neurons for PA patients (Politis & Lindvall,
2012). To test this method of replacing DA-ergic neurons, researchers first transplanted iPSCs
into the striatum of a PD rat model. After evaluation with MRI technology, the animal test
subjects showed some degrees of functional recovery after receiving the iPSC transplants. In
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addition to the apparent success of this method in an animal PD model, an additional advantage
of using iPSCs is that they can be catered to specific patients. However, a downside of iPSCs is
that there have been concerns over the formation of tumors in some test animals after receiving
iPSC transplants. Because of this, more tests need to be done so reliable and safe methods of
treating PD with iPSCs are developed and transitioning to a clinical setting is viable.
Another possible source of stem cells to treat PD is the bone marrow. Bone marrowderived mesenchymal stem cells have been reported to differentiate into neurons that are tyrosine
hydroxylase-positive and improve motor performance in mice (Politis & Lindvall, 2012).
Recently, this research has been expanded into a clinical setting, where a new trial involving
advanced PD patients attempted to discover the abilities of transplanted MSCs to differentiate
into DA-ergic neurons. In the study, PD patients received unilateral transplantations of analogous
bone marrow-derived MSCs into the sublateral ventricular zone of the brain. After 12 months,
the patients reported modest clinical improvement and showed no signs of tumor formation.
Because the research in this trial did not involve collecting MRI or PET scan data before and
after MSC treatment, the mechanisms responsible for these improvements are unfortunately
unknown. Hopefully, future clinical studies designed to treat PD with neurons derived from
MSCs will be able to gain more data on these cells’ abilities.
Although hfVM tissue transplants, iPSCs, and MSCs have all demonstrated the ability to
restore limited amounts of functionality in PD models, PD stem cell research is currently focused
on creating standardized DA-ergic neuroblasts from stem cells. To be successful, it needs to be
demonstrated that the neuroblasts developed for PD treatment cannot only replace lost DA-ergic
neurons but also mitigate the chances of adverse side effects, such as tumor development and
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GIDs (Politis & Lindvall, 2012). If these hallmarks are met, the first demonstration of using stem
cells as an effective restorative treatment for PD patients could soon be seen.
Neurotrophins and Alzheimer’s Disease
Neurotrophic factors serve important roles in the central and peripheral nervous systems
as mediators of cell growth, survival, and homeostatic functions. Of these factors, a few of the
most influential are nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF),
insulin-like growth factor 1 (IFG-1), and glial cell line-derived neurotrophic factor (GDNF)
(Marsh & Blurton-Jones, 2017). Unsurprisingly, it has been shown that these important
neurotrophic factors are decreased in AD patients and animal models. Because of this, research
has begun to investigate the effects of restored levels of neurotrophic factors in AD models to see
increased neuronal health, learning, and memory.
One challenge with this idea is that when delivered by direct injection, many
neurotrophic factors cannot cross the blood-brain barrier. To resolve this issue, it has been
suggested that NSCs could serve as an effective delivery method since they produce a variety of
neurotrophic factors themselves and also migrate extensively (Marsh & Blurton-Jones, 2017). To
test this, researchers used a murine model of AD that exhibited both β-amyloid and tau
pathology. After transplanting NSCs directly into the hippocampus, researchers found that
mouse learning and memory had improved after the observation period. While some may suggest
these results are attributed to the NSCs themselves, researchers in this study found that the test
mice showed significantly elevated brain levels of BDNF after NSC transplantation.
Additionally, in a second trial where AD mice received NSCs with limited BDNR producing
abilities (via shRNA-mediated knockdown), it was discovered that the previously recorded
cognitive and functional restorations were no longer present. In lieu of these results, a subsequent
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study was developed where a different AD model tested the same variables (Zhang et al., 2014).
Again, it was found that transplanted NSCs had no intrinsic effects on Aβ pathology; however,
cognitive restoration was observed in step with increased BDNF levels. From the combination of
these studies, it is clear that in multiple animal AD models, cognitive recovery was observed
following NSC facilitation of BDNF increase.
Since the above results were largely found in AD models where Aβ amyloid
accumulation was the observed pathology, additional research has been conducted on a mouse
model displaying accumulation of hyperphosphorylated tau, a common AD pathology, (Hampton
et al., 2010). To investigate whether increased neurotrophic factors could also lead to cognitive
recovery in this model, researchers in this study transplanted NSCs into the cortex of the tau AD
model. It was found that after NSC transplantation, neuronal loss had been reduced in
comparison to the vehicle treatment. However, this result was not likely due to direct neuronal
differentiation and replacement. This is because the majority of transplanted NSCs were found to
have differentiated into astrocytes, therefore not explaining the observed neuronal recovery. To
confirm that direct neuronal replacement was not the source of reduced neuronal loss, the trials
were repeated using astrocytes (no differentiation capabilities) instead of NSCs, and it was found
that neuronal loss was reduced to a similar degree. After these trials were completed, researchers
were able to examine mRNA levels of key neurotrophic factors and found that while BDNF and
NGF were unchanged, GDNF levels had been increased 4-fold after NSC transplantation and
when compared to the vehicle. This suggests that the neurotrophic factor GDNF may also be
essential to limiting the loss of neurons in tau AD models. As demonstrated by the previously
described studies, it is clear that neurotrophins play essential roles in neurological recovery and
that NSCs show promise as an effective delivery method in AD models. Further investigation
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into this area should focus on developing NSCs that produce high levels of neurotrophins and
therefore may yield greater degrees of neurological recovery.
Neurotrophins and Parkinson’s Disease
In a similar way to AD, PD is also known to exhibit the loss of neurotrophic factors in the
brain. Of these neurotrophic factors, BDFN and GDNF, specifically, have been shown to affect
the survival and function of DA neurons in the midbrain. If the levels of these key neurotrophic
factors can be restored to normal levels, it is hopeful that DA neuronal loss can be limited and
restored in PD patients.
Several studies designed to test this theory used NSCs with greater than normal GDNF
expression (GDNF++) to enhance DA neuron transplantation. In one study, a rat model of PD was
given transplants of DA neurons and GDNF++ NSCs and it was found that post-transplantation,
the rats exhibited decreased DA neuronal degeneration (Akerud et al., 2001). Because of these
results, subsequent studies have been conducted to investigate whether human NSCs modified to
express different neurotrophins can both protect DA neurons and limit motor deficits. It was
found that transplanting NSCs with an overexpression of IGF-1 and GDNF resulted in reduced
DA neuronal loss (Ebert et al., 2008). Additionally, while it was discovered that significantly
more NSCs that were modified to express IGF-1 survived the transplantation process than those
that were modified to express GDNF, both grafts of NSCs resulted in similar neuronal survival
and behavioral recovery (Marsh & Blurton-Jones, 2017). This suggests that GDNF may be a
more potent influencer of neuronal survival.
While the animal trials described in these studies show that neurotrophin-producing
NSCs are indeed effective at preventing DA neuronal degradation, it is important to note that the
majority of clinical PD cases show an α-synuclein pathology which is not shown in these trials
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and is likely to influence PD pathology. To investigate this complication, a novel study involving
an animal model of synucleinopathy showed that after receiving BDNF-producing NSC
transplants, both motor and cognitive recovery was observed (Goldberg et al., 2015). While the
animal model used for this trial was more representative of the neurological disorder, dementia,
the results undoubtedly show that neurotrophic factors have a large effect on motor and cognitive
recovery in an animal model of synuclein pathology. In combination with the PD model
NSC/neurotrophin studies, the results of this research show that neurotrophins are of great
importance for the future of PD research.
Application for Stroke Recovery
Stroke, which occurs when blood supply to part of the brain is interrupted, leading to
dead and damaged neural tissue, is the primary cause of long-term disability in the United States
and the second leading cause of death worldwide. In the wake of this massive epidemic, a large
wave of clinical trials has begun to test the effectiveness of different therapeutics. Unfortunately,
only tissue plasminogen activator (tPA) is FDA approved to treat stroke in humans (Baker et al.,
2017). The largest problem with this specific treatment is that it is only viable for treating one
type of stroke (ischemic stroke) and also serves primarily to limit ischemic damage. tPA
currently has no regenerative functions that would allow patients to achieve neurological
recovery from restored brain tissue. Since the scope of tPA is heavily limited, new methods of
treatment for stroke patients must be found to resolve this issue.
A recent study involving induced pluripotent stem cells (iPSCs) has shown that these
stem cells can be generated from a patient’s somatic cells. From there, they model similar
plasticity to embryonic stem cells and therefore can differentiate into induced neural stem cells
(iNSCs) (Baker et al., 2017). Previous research has shown these neural stem cells are capable of
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effectively bringing about neurological recovery in rodent models of ischemic stroke. They do
this in two different ways: by differentiating into neurons that replace those lost due to stroke
neurological damage, and by producing regenerative and neuroprotective factors that affect
parenchymal healing. In this rodent model, researchers found transplanted iNSCs capable of
reducing tissue atrophy, promoting angiogenesis, inducing glial scar formation, and promoting
many different mature neuronal cell types. While these results seem very promising, key
functional and physiological differences exist between the rodent brain and the human brain,
making the results of this study questionable for human application. In particular, human brains
contain prominent differences from rodent brains in their gray to white matter composition,
blood flow, gyral patterning, and metabolism. These areas are widely affected by stroke, and
therefore, it is important to achieve results in model animals that will show a direct correlation to
humans.
In a different study designed to test a new animal model for stroke, pigs were selected for
a stroke therapy model. Compared to the rodent brain, the pig brain contains much more similar
anatomical and physiological structures to that of the human brain, including those important
characteristics previously described (Baker et al., 2017). In the trials of this study, iNSCs were
first transplanted into the stroke model pigs before non-invasive longitudinal magnetic resonance
imaging (MRI) was performed. The results of this screening showed that after iNSC injection,
stroked animals showed improvements in white matter integrity, brain metabolism, and cerebral
blood perfusion. In addition to these discoveries, it was also found that iNSC therapy yielded
neurogenesis, neural protection, and decreased microglial activation. For the first time, a
transitional large animal model demonstrated that iNSCs show great regenerative and restorative
potential.
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Clinical Trials

In response to the wealth of data gained from animal trials of neural stem cell
transplantation, certain clinical trials have been approved for using NSCs to treat ischemic stroke
in humans. One of these trials, the CTX Pilot Investigation Stem Cells in Stroke (PISCES) Phase
I has recently been completed in the first human trial of stem cell therapy to treat stroke in the
United Kingdom (Sinden et al., 2017). Because of the risks associated with transplanting any
outside organic material into the human body, this trial was only viable after extensive animal
trials and safety tests. These animal trials largely utilized rats with chronic stroke and
demonstrated improvements in behavior and long-term safety. In the PISCES trial, men of at
least 60 years of age who were living with chronic stroke were able to receive doses of CTX
NSCs in amounts of 2, 5, 10, or 20 million by stereotactic ipsilateral putamen injection. In this
pilot human trial, researchers were primarily interested in assessing the safety and tolerability of
CTX transplants as well as observing any neurological and functional outcomes in patients over
24 months.
After collecting data over the trial period of 24 months, researchers of the PISCES Phase
I trial reported no cell-related adverse events in patients. From imaging during the CTX injection
procedure, serious adverse events (SAEs) were reported in 4 out of 11 patients. Of these SAEs,
none were discovered to be symptomatic (Sinden et al., 2017). While previous trials of neuronal
cell implantation have raised concerns about causing seizures in patients, no such events were
found in any patients during the Phase I trial of CTX, an initially promising result.
After CTX NSC transplantation was complete, numerous scales were used to monitor
efficacy in patients. Among these scales were a modified Rankin Scale (mRS), NIH stroke scale
(NIHSS), Ashworth Scale for upper- and lower limb spasticity, and the Barthel Index of

NEURAL STEM CELL THERAPY

24

activities of daily living (BI) (Sinden et al., 2017). Using these scales, patients were assessed
closely for any improvements in the above criteria. Following CTX implantation, it was found
that statistically significant improvements were seen in NIHSS, and non-significant
improvements were seen in the summed scores of the arm and leg Ashworth scale and the BI
index. While the improvements displayed by these scaled are remarkable, not every patient in
this trial showed signs of recovery. In 7 out of 11 patients, disability, as measured by the mRS
was found to be unchanged after 12 months, and in the remaining 4 patients, it only improved by
one grade. At the end of the trial period of 24 months, disability was still unchanged in 7
patients, was worsened by two grades in one patient, and had improved by one grade in three
patients.
In addition to the scale used by researchers to monitor results, patients in this study also
had the option to report their overall health statuses. When compared to the baseline, patients
reported that their health had improved by a median of 18 points (interquartile range -5 to 30)
after 12 months (Sinden et al., 2017). As an additional method of gathering data, functional
magnetic resonance imaging (fMRI) was also used both pre and post-treatment to screen for
neurological developments. From this data, it was found that changes in patients’ motor
activation were consistent with fMRI measured neurological improvement.
Since the PISCES Phase I trial involved a very small number of treated individuals, a
heterogeneous study population, and a single-arm design, reliable conclusions could not be
drawn about neurological and functional recovery after CTX NSC implantation. Any such
conclusion would apply only to the population of individuals tested and would need more trials
involving outside controls to avoid confounding factors. This being said, it is worthwhile to note
that despite the trial’s population of patients being in the late stages of chronic stroke, many of
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the individuals treated in this phase showed improvement in different areas (Sinden et al., 2017).
While it is unknown whether these improvements can be linked to stem cell implantation or
outside factors such as increased medical attention, this study seems to cast doubt on the regular
assumption among clinicians that late-stage chronic stroke cannot be treated. In addition to the
improvements documented above, it should also be noted that multiple patients in Phase I of this
trial were found to report occasional and unmeasured instances of minor return of finger
movement, improved visual perception, reduced spasticity, and better bed-to-chair transfers. It is
hopeful that in later phases of the PISCES trial, measures will be taken to ensure that these
improvements can be quantified and reported.
In this pilot trial, men, as opposed to a mixed group of men and women, were selected
and enrolled, due to the lack of reproductive toxicology reports for stem cell studies of any
origin. This was especially relevant to this trial where a tamoxifen metabolite analog receptor is
used to control cell manufacture of CTX (Sinden et al., 2017). While tamoxifen has been found
to affect the female reproductive system in other cases, future clinical studies of CTX may
involve female participation as preclinical studies of CTX NSC transplantation in both male and
female stroke animal models did not show any negative events. In addition to the lack of mixedgender participants, a unique feature of this trial was a lack of immunosuppressive therapy. This
was supported by the knowledge that nonclinical studies of CTX showed no evidence that
immunosuppression would be required for either cell survival or differentiation. Further,
immunosuppression was seen as an unnecessary risk as it has been previously linked to infection
after stroke (Stroemer et al., 2009). This, with the knowledge that test subjects in this trial were
individuals with preexisting conditions, made limiting the risk of infection an essential
component of Phase I.
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Due to successes in the demonstration of safety and in obtaining useful data in the Phase I
trial of PISCES, a second trial, Phase II, was formed. In this second clinical trial, patients who
were experiencing single-arm paresis after suffering an ischemic stroke were able to receive a
single dose of 20 million CTX NSCs (Sinden et al., 2017). This phase tested the feasibility of
using CTX to treat single-arm paresis over 12 months and showed that a sufficient proportion of
the test population experienced some functional recovery. The study also determined that CTX
treatment was both safe and tolerable, with the majority of adverse side effects reported by
patients being related to the surgical procedure itself (Muir et al., 2020). To test the results of this
study, similar scales of recovery as used in PISCES Phase I were incorporated, including the
NIHSS, a more objective version of mRS, and BI. PISCES Phase II, being a successful study of
CTX treatment for single-arm paresis after ischemic stroke, will pave the way for a subsequent
larger clinical study, PISCES III, which is currently in development.
Conclusion
By replacing damaged neural tissue, fighting inflammation and immune responses,
delivering neurotrophic factors to areas of deficit, and much more, neural stem cells show
remarkable abilities that are not seen in other cells of the body. Although neurological disease is
currently widespread in both the United States and the rest of the world, it is hopeful that one
day, NSC research may allow those suffering from disorders such as Alzheimer’s disease,
Parkinson’s disease, and stroke to finally experience recovery. While more research needs to be
conducted before this goal becomes a reality, the rate of discovery in neural stem cell research
over the last couple of decades is astonishing. With this in mind, it is within reason to hope that
breakthroughs in NSC research will continue to be made in the next decade, and the one after
that, until neurological disease is a concern of the past.
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